TransCode Therapeutics, Inc.

NASDAQ: RNAZ · Healthcare · Biotechnology

PublicHQ Boston, MA · SuffolkCIK 0001829635Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 57DQ —GM —SS 29

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, return on assets · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$34.7M

Employees

as of 2026-08-23

Market cap

$3.0M

as of 2026-08-23

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$34.7M-$34.7M2025

Operating income-$28.0M-$28.0M2025

Total assets$162.4M$162.4M2025

Liabilities$10.5M$10.5M2025

Equity$10.3M$10.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is TransCode Therapeutics, Inc.’s financial profile?

TransCode Therapeutics, Inc. earned -$34.7M in FY2025 net income.

Peers · Healthcare

CTT Pharmaceutical Holdings, Inc.——MetaVia Inc.——Standard Dental Labs Inc.——Enzolytics Inc.——FibroBiologics, Inc. Common Stock——Strainsforpains, Inc.——

Neighbors

Suffolk →

Vertex Pharmaceuticals Incorporated$12.0B88A American Tower Corporation$935.9M76B+State Street Corporation$13.9B67B NSTAR Electric Company——Toast, Inc.$6.2B67B PTC Inc.$2.7B83B+

Key facts

CEOPhilippe Calais

SectorHealthcare

IndustryBiotechnology

HeadquartersBoston, MA

ExchangeNASDAQ: RNAZ

Employees12

IPO date2021-07-08

Latest filings

10-Q2026-08-14 8-K2026-08-03 8-K2026-07-20 8-K2026-07-17 8-K2026-07-02 8-K2026-06-18 8-K2026-06-03 DEF 14A2026-06-02

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.